224 related articles for article (PubMed ID: 27388232)
21. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
22. The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer.
Nisman B; Maimon O; Allweis T; Kadouri L; Maly B; Hamburger T; Peretz T
Anticancer Res; 2013 Jan; 33(1):293-9. PubMed ID: 23267160
[TBL] [Abstract][Full Text] [Related]
23. Associations of insulin resistance and adiponectin with mortality in women with breast cancer.
Duggan C; Irwin ML; Xiao L; Henderson KD; Smith AW; Baumgartner RN; Baumgartner KB; Bernstein L; Ballard-Barbash R; McTiernan A
J Clin Oncol; 2011 Jan; 29(1):32-9. PubMed ID: 21115858
[TBL] [Abstract][Full Text] [Related]
24. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
26. The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesity.
Komosinska-Vassev K; Gala O; Olczyk K; Jura-Półtorak A; Olczyk P
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32917052
[TBL] [Abstract][Full Text] [Related]
27. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Cancer; 2015 Nov; 121(22):3965-74. PubMed ID: 26249241
[TBL] [Abstract][Full Text] [Related]
28. Clinical pathological characteristics of breast cancer patients with secondary diabetes after systemic therapy: a retrospective multicenter study.
Juanjuan L; Wen W; Zhongfen L; Chuang C; Jing C; Yiping G; Changhua W; Dehua Y; Shengrong S
Tumour Biol; 2015 Sep; 36(9):6939-47. PubMed ID: 25854171
[TBL] [Abstract][Full Text] [Related]
29. Insulin resistance, growth factors and cytokine levels in overweight women with breast cancer before and after chemotherapy.
Chala E; Manes C; Iliades H; Skaragkas G; Mouratidou D; Kapantais E
Hormones (Athens); 2006; 5(2):137-46. PubMed ID: 16807226
[TBL] [Abstract][Full Text] [Related]
30. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
31. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.
Montagna E; Vingiani A; Maisonneuve P; Cancello G; Contaldo F; Pruneri G; Colleoni M
Breast; 2017 Aug; 34():83-88. PubMed ID: 28544923
[TBL] [Abstract][Full Text] [Related]
32. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
[TBL] [Abstract][Full Text] [Related]
33. Is glycosylated hemoglobin A1c a surrogate for metabolic syndrome in nondiabetic, first-degree relatives of African-American patients with type 2 diabetes?
Osei K; Rhinesmith S; Gaillard T; Schuster D
J Clin Endocrinol Metab; 2003 Oct; 88(10):4596-601. PubMed ID: 14557428
[TBL] [Abstract][Full Text] [Related]
34. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
35. Impact of triple negative phenotype on breast cancer prognosis.
Kaplan HG; Malmgren JA
Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
[TBL] [Abstract][Full Text] [Related]
36. Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients.
Kim JY; Lee DW; Lee KH; Min A; Ryu HS; Lee HB; Moon HG; Kim TY; Han SW; Oh DY; Han W; Park IA; Noh DY; Im SA; Kim S
Breast Cancer Res Treat; 2019 Jul; 176(2):453-460. PubMed ID: 31028608
[TBL] [Abstract][Full Text] [Related]
37. Insulin and leptin levels in obese patients with and without breast cancer.
Romero-Figueroa Mdel S; Garduño-García Jde J; Duarte-Mote J; Matute-González G; Gómez-Villanueva A; De la Cruz-Vargas J
Clin Breast Cancer; 2013 Dec; 13(6):482-5. PubMed ID: 24084031
[TBL] [Abstract][Full Text] [Related]
38. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.
Mittendorf EA; Vila J; Tucker SL; Chavez-MacGregor M; Smith BD; Symmans WF; Sahin AA; Hortobagyi GN; Hunt KK
JAMA Oncol; 2016 Jul; 2(7):929-36. PubMed ID: 26986538
[TBL] [Abstract][Full Text] [Related]
39. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.
Mulligan AM; O'Malley FP; Ennis M; Fantus IG; Goodwin PJ
Breast Cancer Res Treat; 2007 Nov; 106(1):39-47. PubMed ID: 17221153
[TBL] [Abstract][Full Text] [Related]
40. CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer.
Tunca B; Egeli U; Cecener G; Tezcan G; Gökgöz S; Tasdelen I; Bayram N; Tolunay S; Umut G; Demirdogen E; Erturk E; Ak S; Cetintas S; Evrensel T
Tumori; 2012; 98(2):243-51. PubMed ID: 22677992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
